Spojené štáty - angličtina - NLM (National Library of Medicine)

sagent pharmaceuticals - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology - susceptibility testing ). oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected

Spojené štáty - angličtina - NLM (National Library of Medicine)

fresenius kabi usa, llc - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.  cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology -susceptibility testing ). oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results.  oxacillin should not be used in infections caused by organisms susceptible to penicillin g.  if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspec

Spojené štáty - angličtina - NLM (National Library of Medicine)

armas pharmaceuticals inc. - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (see clinical pharmacology - susceptibility test methods ). oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

hospira uk limited - piperacillin sodium ; tazobactam sodium - pdr for soln inj/inf - 4000/500 milligram - piperacillin and enzyme inhibitor

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

azure pharmaceuticals ltd - flucloxacillin sodium - film-coated tablet - flucloxacillin

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

azure pharmaceuticals ltd - flucloxacillin sodium - film-coated tablet - flucloxacillin

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - flucloxacillin sodium - oral capsule - 500mg

Kanada - angličtina - Health Canada

teva canada limited - cloxacillin sodium - powder for solution - 500mg - cloxacillin sodium 500mg - penicillinase-resistant penicillins

Kanada - angličtina - Health Canada

sterimax inc - cloxacillin (cloxacillin sodium) - powder for solution - 500mg - cloxacillin (cloxacillin sodium) 500mg - penicillinase-resistant penicillins

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate - eq. flucloxacillin 500 mg - powder for solution for injection/infusion - 500 mg - flucloxacillin 500 mg - flucloxacillin